Goldman Sachs has raised its price target for Danish pharmaceutical company Novo Nordisk to 436 Danish kroner (from 352). The "Buy" recommendation is reiterated.

In its analysis, the bank assesses that the company's recently launched Wegovy pill will act as a driver for sentiment in the short term, according to Bloomberg News. The pill is also expected to contribute to positive earnings development in the near term.

Novo Nordisk closed at 373.85 Danish kroner on Wednesday. The stock is up 2.9 percent on Thursday.